Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21598618 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL5218067 | 0.82 | SYK (0.39) | SMN1; SMN2ALDH1A1MAPTL3MBTL1GAA | |
| SCHEMBL29955740 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL1560993 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL23628498 | 0.73 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL29572157 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EMAPTGAA | |
| SCHEMBL21598601 | 0.71 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL18668393 | 0.71 | CA2 (0.48) | SMN1; SMN2ALDH1A1MAPTL3MBTL1CYP1A2 | |
| SCHEMBL29572192 | 0.71 | CA2 (0.48) | SMN1; SMN2ALDH1A1MAPTL3MBTL1CYP1A2 | |
| SCHEMBL3928750 | 0.71 | RAB9A (0.58) | SMN1; SMN2ALDH1A1MAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101490055-B | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH | 2013-10-16 | — | — | CN | disclosed |
| EP-2041142-B1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8399503-B2 | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| CN-101490055-A | Spirocyclic azaindole derivatives | GRUENENTHAL GMBH (DE) | 2009-07-22 | — | — | CN | disclosed |
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | GRUNENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2041142-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009416-A1 | SPIROCYCLIC AZAINDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156593-A1 | Spirocyclic Azaindole Derivatives | AZI2, TPMT, AADAC | SMN1; SMN2 4555/4885ALDH1A1 709/4885KDM4E 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.